DrugIP ...

Structural relationships of drugs

edit
edit

see in edit mode Linezolid a weak monoamine oxidase inhibitor (MAOI)

Drug vs mechanism of pancreatitis

edit
Drug Name: In Frequency of occurrence References No. of Reported Cases No. of Cases Following Re-exposure Age Range of Patients (yr) Class & e.g. Mechanism of the class: & individual drugs Mechanism of pacreatitis SAR-others in class: Mechanism Parsing Basic Mechanisms Class X ref match 1 to... Basic Mechanisms Class X ref match ... n
Didanosine 13–17 883 9 2.5–61 A. Anitmicrobials

1. Antivirals a. Nucleoside reverse transcriptase inhibitors Abacavir, Didanosine, Lamivudine, Stavudine, Zalcitabine, Zidovudine

Inhibition of mitochondrial DNA polymerase-gamma leads to impaired oxidative phosphorylation and failure to synthesize ATP
Asparaginase 18–22 177 2 2 –75 D. Antineoplastic agents 2. Leukemia medications

e.g. Asparaginase, Pegasparaginase in acute lymphoblastic leukemia (ALL)

cystic fibrosis transmembrane conductance regulator (CFTR) gene have been associated with pancreatitis in people without cystic fibrosis.
Drug Name: In Frequency of occurrence References No. of Reported Cases No. of Cases Following Re-exposure Age Range of Patients (yr) Class & e.g. Mechanism of the class: & individual drugs Mechanism of pacreatitis SAR-others in class: Mechanism Parsing Basic Mechanisms Class X ref match 1 to... Basic Mechanisms Class X ref match ... n
Azathioprine 23–27 86 16 11–65 F. GI agents

3. IBD medications a. Aminosalicylates Balsalazide, Mesalamine, Olsalazine, Sulfasalazine b. Others Azathioprine, Mercaptopurine

antagonist to purine metabolism, may inhibit RNA and DNA synthesis.

Thedrug may also be incorporated into nucleic acids resulting in chromosome breaks, malfunctioning of the nucleic acids, or synthesis of fraudulent proteins. the drug may also inhibit coenzyme formation and functioning, thereby interfering with cellular metabolism. Mitosis may be inhibited by the drug.

Valproic acid 80 11 1–65 C. Neuropsychiatric agents

1. Anticonvulsants Carbamazepine, Divalproex sodium, Felbamate, Gabapentin, Lamotrigine, Topiramate, Valproic acid

Reduction of superoxide dismutase, catalase, and glutathione peroxidase, which are in charge of removing free radicals. The increase of free radicals can lead to an increase of endothelial permeability and lipid peroxidation
Pentavalent antimonials 33–40 80 14 19–62 Sodium stibogluconate and Ureastibamine Specifically inhibit the relaxation of supercoiled plasmid pBR322 catalyzed by DNA topoisomerase I of Leishmania donovani. Dose dependent inhibition suggests that the drugs interact with the enzyme rather than the DNA pancreatitis subsides when therapy is stopped, and rechallenge may be tolerated after a brief halt in treatment
Drug Name: In Frequency of occurrence References No. of Reported Cases No. of Cases Following Re-exposure Age Range of Patients (yr) Class & e.g. Mechanism of the class: & individual drugs Mechanism of pacreatitis SAR-others in class: Mechanism Parsing Basic Mechanisms Class X ref match 1 to... Basic Mechanisms Class X ref match ... n
Pentamidine 41–45 79 2 14–63 Glucose abnormalities, renal insufficiency, and non-specific abdominal pain may be early warning signs of pentamidine-associated pancreatitis.
Mercaptopurine 46–50 69 10 6–40 Treat leukemia, pediatric non-Hodgkin's lymphoma,[citation needed] polycythemia vera,[2] psoriatic arthritis,[3] and inflammatory bowel disease (such as Crohn's disease and ulcerative colitis 6-MP ribonucleotide inhibits purine nucleotide synthesis and metabolism. This alters the synthesis and function of RNA and DNA. Mercaptopurine interferes with nucleotide interconversion and glycoprotein synthesis. Patients exhibiting myelosuppression or bone marrow toxicity should be tested for thiopurine methyltransferase (TPMT) enzyme deficiency. Patients with TPMT deficiency are much more likely to develop dangerous myelosuppression.[6] In such patients, it may be possible to continue using mercaptopurine, but at a lower dose
Mesalamine 51–55 59 18–43 Sulphasalazine is an active agent in the treatment of chronic inflammatory bowel disease Sulphasalazine is composed of sulphapyridine and mesalazine (5-aminosalicylic acid, 5-ASA or mesalazine) joined by an azo bond 5-aminosalicylic acid (5-ASA) is the active moiety of sulphasalazine

Various estrogens56–60 42 11 21–53 Opiates61–65 42 5 8–74 Tetracycline60,66–68 34 2 10–72 Cytarabine69–72 26 4 14–73 Steroids73–77 25 1 2–88 Sulfamethoxazole/trimethoprim78–81 24 1 26–62 Sulfasalazine82–84 23 5 12–54 Furosemide85–88 21 3 23–74 Sulindac89–93 21 8 31–91 Class II Rifampin94 25 0 57 Lamivudine95 19 1 34–63 Octreotide96–99 16 4 24–66 Carbamazepine100–102 14 0 5–73 Acetaminophen103–106 13 1 19–74 Phenformin*,107–111 13 1 39–87 Interferon-afa 2b112–114 12 2 38–54 Enalapril115–119 12 2 23–69 Hydrochlorothiazide120 12 1 11–72 Cisplatin121 11 1 9–41 Erythromycin106,122–124 11 1 12–75 Cyclopenthiazide*,125 11 0 ?

Drug Name: In Frequency of occurrence References No. of Reported Cases No. of Cases Following Re-exposure Age Range of Patients (yr) Class & e.g. Mechanism of the class: & individual drugs Mechanism of pacreatitis SAR-others in class: Mechanism Parsing Predicting Protein Ligand Binding Sites by Combining Evolutionary Sequence Conservation and 3D Structure Basic Mechanisms Class X ref match 1 to... Basic Mechanisms Class X ref match ... n



  • diabetes-drugs-may-cause-damage-to-pancreas
  • Liraglutide (Victoza)-It has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies).
  • Exenatide (Byetta)
  • Albiglutide
  • Taspoglutide

References

edit
edit